The power of data and market trends impacting pharmaceutical manufacturing and R&D facilities

Introduction

The global pharmaceutical industry is witnessing a surge in CEO confidence from US tax reforms, turbulent equity markets, and the strengthening global economy. The growth of the pharmaceutical industry is boosted by healthcare digitalization and democratization, creating an explosion in patient data, and the emergence of value-based reimbursement models. The convergence of biopharmaceuticals, drug delivery devices, and companion diagnostics—enabled by digital connectivity—is driving regulatory and commercial changes in many exciting ways for the industry.

Click here to Read More

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success.

Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success.

Share This